In vitro and clinical evaluation of platelet-rich plasma combined with angioplasty in diabetic foot treatment

Figure 5 Validation of the vascular endothelial growth factor receptor signaling pathway in human umbilical vein endothelial cells. A: Visualization of the relative expression levels of Ak strain transforming (Akt) and extracellular regulated protein kinases 1/2 (ERK1/2) in human umbilical vein endothelial cells (HUVECs) in each treatment group; B: Statistical analysis of the relative expression levels of ERK1/2 in HUVECs in each treatment group; C: Statistical analysis of the relative expression levels of Akt in HUVECs in each treatment group; D: Standard curve of vascular endothelial growth factor receptor (VEGFR2); E: Analysis of VEGFR2 expression levels in HUVECs in each treatment group; F: Standard curve of p38; G: Analysis of p38 expression levels in HUVECs in each treatment group. Significant differences in experimental data were analyzed using t tests, and all assays were performed in triplicate. ^aP < 0.05 vs the control (CTRL) group; ^cP < 0.001 vs the CTRL group. Akt: Ak strain transforming; ERK1/2: Extracellular regulated protein kinases 1/2; HUVECs: Human umbilical vein endothelial cells; PRP: Platelet-rich plasma; CTRL: The control group.